INDIANAPOLIS, Jan 08, 2008 -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil)(1) for once daily use (2.5 mg and 5 ...
Men with prostate cancer who are treated with radiation therapy shouldn't count on using the drug tadalafil (brand name: Cialis) to prevent erectile dysfunction, according to a study published today ...
INDIANAPOLIS, Oct. 7, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil) tablets for once daily ...
Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to ...
Currently only available with a prescription, Cialis is a tablet taken to treat erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and both ED and the signs and ...
Cialis OK'd to treat benign prostatic hyperplasia FDA has approved expanded use of Cialis Drug brought in 8% of Lilly's revenue INDIANAPOLIS (AP) — The European Union has approved Eli Lilly and Co.'s ...
Sanofi on Monday announced an actual use trial of its Cialis erectile dysfunction treatment was put on clinical hold in the United States by the Food and Drug Administration (FDA). PARIS, May 30 ...
The European Union has approved Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged prostate. Lilly, based in Indianapolis, said Tuesday the commission approved ...
Paris. May 30, 2022. The U.S. Food and Drug Administration has informed Sanofi that its planned Actual Use Trial (AUT) to support the Rx-to-OTC switch for Cialis® (tadalafil) has been placed on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results